Aura Biosciences (AURA) Competitors $6.32 +0.16 (+2.58%) Closing price 03:59 PM EasternExtended Trading$6.33 +0.01 (+0.17%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AURA vs. SDGR, HROW, SNDX, EVO, ZYME, AVDL, TSHA, ORIC, SION, and XERSShould you be buying Aura Biosciences stock or one of its competitors? The main competitors of Aura Biosciences include Schrodinger (SDGR), Harrow (HROW), Syndax Pharmaceuticals (SNDX), Evotec (EVO), Zymeworks (ZYME), Avadel Pharmaceuticals (AVDL), Taysha Gene Therapies (TSHA), Oric Pharmaceuticals (ORIC), Sionna Therapeutics (SION), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry. Aura Biosciences vs. Its Competitors Schrodinger Harrow Syndax Pharmaceuticals Evotec Zymeworks Avadel Pharmaceuticals Taysha Gene Therapies Oric Pharmaceuticals Sionna Therapeutics Xeris Biopharma Aura Biosciences (NASDAQ:AURA) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings. Do institutionals and insiders believe in AURA or SDGR? 96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 6.3% of Aura Biosciences shares are owned by insiders. Comparatively, 21.0% of Schrodinger shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media refer more to AURA or SDGR? In the previous week, Aura Biosciences and Aura Biosciences both had 4 articles in the media. Aura Biosciences' average media sentiment score of 0.81 beat Schrodinger's score of 0.36 indicating that Aura Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Schrodinger 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer AURA or SDGR? Aura Biosciences presently has a consensus target price of $22.00, indicating a potential upside of 248.16%. Schrodinger has a consensus target price of $26.29, indicating a potential upside of 27.52%. Given Aura Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Aura Biosciences is more favorable than Schrodinger.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aura Biosciences 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78Schrodinger 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38 Which has more volatility and risk, AURA or SDGR? Aura Biosciences has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.74, meaning that its share price is 74% more volatile than the S&P 500. Which has higher earnings and valuation, AURA or SDGR? Aura Biosciences has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAura BiosciencesN/AN/A-$86.92M-$1.96-3.22Schrodinger$207.54M7.31-$187.12M-$2.48-8.31 Is AURA or SDGR more profitable? Aura Biosciences has a net margin of 0.00% compared to Schrodinger's net margin of -76.22%. Schrodinger's return on equity of -45.70% beat Aura Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Aura BiosciencesN/A -64.44% -54.24% Schrodinger -76.22%-45.70%-24.81% SummaryAura Biosciences beats Schrodinger on 10 of the 15 factors compared between the two stocks. Get Aura Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AURA vs. The Competition Export to ExcelMetricAura BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$392.54M$3.39B$6.04B$10.49BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-3.2222.9085.1927.32Price / SalesN/A269.18516.16194.55Price / CashN/A46.9537.5761.53Price / Book2.0810.5312.426.81Net Income-$86.92M-$52.58M$3.32B$276.59M7 Day Performance3.76%1.06%0.80%0.15%1 Month Performance5.85%16.05%10.52%8.17%1 Year Performance-35.91%18.41%76.14%35.50% Aura Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AURAAura Biosciences1.9856 of 5 stars$6.32+2.6%$22.00+248.2%-34.0%$392.54MN/A-3.2250High Trading VolumeSDGRSchrodinger2.6422 of 5 stars$19.70+3.2%$26.29+33.4%+9.0%$1.40B$207.54M-7.94790Analyst ForecastHROWHarrow2.7602 of 5 stars$38.77+3.4%$68.50+76.7%-22.7%$1.39B$199.61M-155.08180SNDXSyndax Pharmaceuticals3.6399 of 5 stars$15.20-5.4%$39.22+158.0%-22.8%$1.38B$23.68M-3.91110EVOEvotec2.0058 of 5 stars$3.95+2.1%$7.00+77.2%+31.1%$1.37B$862.40M0.004,827ZYMEZymeworks2.3156 of 5 stars$18.11+0.3%$22.50+24.2%+37.1%$1.36B$122.87M-12.07460News CoverageAnalyst ForecastAVDLAvadel Pharmaceuticals2.7138 of 5 stars$14.20+1.4%$20.86+46.9%+9.1%$1.36B$169.12M-473.3370TSHATaysha Gene Therapies2.4035 of 5 stars$5.05+3.5%$9.00+78.2%+159.3%$1.33B$8.33M-14.85180Gap UpORICOric Pharmaceuticals4.2939 of 5 stars$13.91+1.7%$17.29+24.3%+37.9%$1.33BN/A-7.3680Gap UpSIONSionna Therapeutics2.7158 of 5 stars$29.31-0.4%$38.00+29.6%N/A$1.30BN/A0.0035XERSXeris Biopharma2.983 of 5 stars$7.95-0.5%$7.08-10.9%+173.4%$1.29B$203.07M-37.86290News CoverageAnalyst Upgrade Related Companies and Tools Related Companies Schrodinger Competitors Harrow Competitors Syndax Pharmaceuticals Competitors Evotec Competitors Zymeworks Competitors Avadel Pharmaceuticals Competitors Taysha Gene Therapies Competitors Oric Pharmaceuticals Competitors Sionna Therapeutics Competitors Xeris Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AURA) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aura Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aura Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
